Showing results (81-90 of 378) with videos related to
Sort By:
Pageof 38
The Oncologist|December 25, 2019
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)Kaushal Parikh, Sumithra J Mandrekar, Katie Allen-Ziegler, et al.Journal of Cachexia, Sarcopenia and Muscle|September 17, 2020
Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patientsJennifer Le-Rademacher, Camden Lopez, Eric Wolfe, et al.Cancer|November 20, 2009
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaEric W Schaefer, Shaji Kumar, Angela Dispenzieri, et al.Journal of the American Statistical Association|February 15, 2011
CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATHKeunbaik Lee, Michael J Daniels, Daniel J SargentClinical Medicine Insights. Oncology|May 24, 2011
Systemic therapy for elderly patients with gastrointestinal cancerJoleen M Hubbard, Axel Grothey, Daniel J SargentJournal of Biopharmaceutical Statistics|June 7, 2014
Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End PointsLindsay A Renfro, Hongwei Shang, Daniel J SargentTransactions of the American Clinical and Climatological Association|August 11, 2010
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogeneticsRichard M Goldberg, Daniel J Sargent, Howard McLeodChinese Clinical Oncology|April 6, 2015
Mining the ACCENT database: a review and updateLindsay A Renfro, Qian Shi, Daniel J SargentMayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.Biometrics|August 16, 2011
Bayesian adaptive trial design for a newly validated surrogate endpointLindsay A Renfro, Bradley P Carlin, Daniel J SargentPageof 38